Tue 6/19/2018 06:22 ET
DJIA24987.47103.010.41%TELCO155.413.001.93%GOLD1281.401.280.10%Shanghai2907.82109.923.78%
S&P 5002773.875.830.21%BANKS468.790.840.18%OIL64.880.811.25%BITCOIN6732.2117.500.26%
NASDAQ7747.030.770.01%PHARM504.115.341.06%US/EU1.170.000.26%Futures2748.5031.251.14%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Wall Street Pit (Pivot Pharmaceuticals Inc - PVOTF)    Stock Due Diligence for All

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add PVOTF
  
From: NetworkNewsWire (Rep: 0)Date: 03/13/2018 20:56
Forum: Wall Street Pit - Msg #2724513 - List PVOTF msgs Thread #673997268 (Rec: 0)
Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) Finding Ever-Growing Ways to Administer Cannabis Benefits

- Pivot Pharmaceuticals developing disruptive formulations for cannabis-infused markets
- Company’s goal is to strengthen dosage predictability and improve product stability
- Recent acquisitions and planned acquisitions give Pivot vertical position in multi-billion-dollar industries

Despite recent setbacks to efforts seeking broader marijuana legalization in North America (http://nnw.fm/UXnm7), the tide of social preferences for cannabis availability, even in recreational applications, continues to advance (http://nnw.fm/ZZ00n). Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) is helping to advance efforts to legitimize the drug’s use, both in medicinal and recreational settings, by pursuing ever-increasing methods for consuming cannabis’s derivatives in quantities with predictable outcomes.

“Pivot’s goal is to increase cannabinoid bioavailability, drug release rates and improve product stability, and consumers should be able to confidently take correct and accurate doses to help meet their health and wellness needs,” Joseph Borovsky, Pivot’s vice president of product formulation, stated in a recent news release (http://nnw.fm/AiZ6a).

The company has filed continuation patents to maintain its impetus in making cannabis available through powdered formulations that can be combined with existing products in the food and beverage market. That includes health and wellness products such as natural sleep-aids, cold medications and vitamins.

On March 6, Pivot Pharmaceuticals announced its acquisition of Thrudermic, LLC, a North Carolina company invested in a transdermal lipid-based nano-dispersion technology to make cannabis formulations available through external delivery. Thrudermic has filed three new patent applications for Pivot related to better formulation and delivery of its product as the company pursues new routes of drug administration.

Pivot’s acquisition of California’s ERS Holdings, LLC in February not only strengthened its options for enhanced health and wellness products; the move gave the company added visibility to beverage makers such as beer companies working to mitigate a potential decline in profits as their customers divert discretionary income from alcohol consumption to cannabis consumption.

“The (Ready-To-Infuse-Cannabis technology) family of patents will be transformational for the food and beverage industry. Based on our interaction with key players in the beverage market, we anticipate that there will be a significant substitution in consumer choices towards cannabis infused drinks. With this acquisition, we have positioned Pivot to be at the forefront of this enormous new market,” Pivot CEO Patrick Frankham stated in a news release about the acquisition (http://nnw.fm/e8hOI).

The company has also announced plans to acquire Agro-Biotech, a Quebec-based Canadian-licensed cannabis producer (http://nnw.fm/LeZ3q). Agro-Biotech operates a licensed hydroponic cannabis production facility that can turn out 10,000 kilograms per year, giving Pivot a source for its products as it strives to achieve a stronger vertical position in the industry for cannabinoids, cannabidiol (CBD) and tetrahydrocannabinol (THC).

An agreement between Pivot and Germany’s Solmic Research GmbH gave the company rights to technology designed to give cancer patients relief from vomiting, nausea, neutropenia and anemia during chemotherapy treatment. Those side effects trouble an estimated 70 to 80 percent of chemotherapy patients and often lead to the discontinuation of treatment before the illness has been completely addressed, according to Transparency Market Research (http://nnw.fm/8CzeJ). Cannabis’s therapeutic abilities are expected to help it grow into a $55.8 billion market by 2025, according to a 2017 report by Grand View Research (http://nnw.fm/X3ohq), and the cancer supportive care products market is expected to reach $29.87 billion by 2021.

For more information, visit the company’s website at www.PivotPharma.com

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

What would you like to do? Message: Endorse | Bookmark | Report AbuseUser NetworkNewsWire: Reward | Watch | IgnorePVOTF: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add PVOTF
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.